1. Third Party Submission under Art 37 CFR 1.99

TKDL third party submission under Art 37 CFR 1.99 brought to the notice of examination division the prior art references on the use of Terminalia chebula (Haritaki) Terminalia bellirica (Baheda), Phyllanthus emblica (Aamla), Curcuma longa (Turmeric/Haldi), Gymnema sylvestre (Gurmar buti), Momordica charantia (Karela), Holarrhena antidysenterica (Kutaja), Trigonella foenum-graecum (Methi), Mucuna pruriens (Konch) for the treatment of Diabetes mellitus from the books – Rasatantrasarah Evam Siddhaprayogasamgrahah;- part II (Ayurveda, Exhibit 1), TherayarKappiyam by Therayar (Siddha, Exhibit 2), Khazaain-al-Advia, Vol III by Mohammad Najmul Ghani Khan (Unani, Exhibit 3), Ilaaj-al-Amraaz by Mohammad Shareef Khan (Unani, Exhibit 4), Qaraabaadeen Najm-al-Ghani by Mohammad Najmul Ghani Khan (Unani, Exhibit 5) and Bayaaz-e-Kabir by Mohammad Kabiruddin (Unani, Exhibit 6).

2. Relevant Extract of USPTO Examination Report

USPTO Patent Examiner(s) took cognizance of TKDL references. Extract of examination report are reproduced below:

“Claims 1-10 and 12-13 are rejected under 35 U.S.C. 103 (a) as being unpatentable over WIPO Publication (WO 2005/076750), Joel R.L. Ehrenkranz (US 2006/0189512), Dham et al (Current Diabetes Reports, 2006, Vol 6, pages 251-258), Sabu et al. (Pharmaceutical Biology, 2003, Vol.41, No.7, pages 500-505), and Mohammad et al. (Key Attributes of TKDL, formulation JA6/323J)
     The cited reference of Mohammad et al. beneficially teaches a formulation comprising Holarrhena antidysenteric that is useful in the treatment of Diabetes mellitus.”

Full examination report can be referred at 20100173022.pdf

3. Outcomes of Third Party Observations & Examination Report.

As the outcome of TKDL third party and other documents cited in examination report, the examiner decided to reject the claims 1-10 and 12-13 on 19.09.2012 under 35 U.S.C 103 (a). Application was abandoned on 27.03.2013